LYS.PA Stock Analysis
LY
Uncovered
Lysogene SA is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Lysogene SA engages in the research and clinical development of gene therapy for neurodegenerative disorders. The company is headquartered in Neuilly-Sur-Seine, Ile-De-France and currently employs 23 full-time employees. The company went IPO on 2017-02-08. The firm is focused on the gene therapy biotechnology. The firm develops treatments targeting severe genetic pathologies with central nervous system involvement and high unmet medical needs. The company is specialized in the development of intracerebral gene therapy aimed at treating pathologies affecting the central nervous system, which is the main cause of neuro-degenerative disease mortality in children.